Acadia Healthcare Q3 2026: EPS Beats by 29%, Guidance Raised

As seen on the 24/7 Wall St. homepage on November 4, 2026.

ACHC Acadia Healthcare
Q3 2026
EPS
$0.60
est $0.46 +29.2%
Revenue
$895M
est $878M +2.0%

A raise big enough to reset the math on a $3 billion market cap: Acadia Healthcare lifted full-year adjusted EPS guidance to $1.70 to $1.80 from $1.45 to $1.60. Management expects about $60 million of incremental EBITDA in 2027 from the 16 acute facilities opened over the past four years.

Continue ReadingShow less

Acadia Healthcare reported adjusted earnings per share of $0.60 for the third quarter of 2026, well ahead of the consensus estimate of $0.46 and representing a beat of 29.2%. Revenue came in at $895.3 million, topping expectations by roughly 2% and growing 5.1% year over year. GAAP diluted EPS was $0.38, with the gap to the adjusted figure reflecting $23.7 million in transaction, legal, and other costs, partially offset by a $7.2 million legal settlements gain.

The Acute Inpatient Psychiatric segment drove the outperformance, with revenue up 11.3% and volumes up 7.5%. A 144-bed de novo facility opened near Jacksonville, Florida contributed to 220 net new licensed beds added in the quarter, and same-facility admissions grew 6.6%. Revenue per patient day increased 4.0%, though a shorter average length of stay partially offset the volume gains. Adjusted EBITDA reached $176.4 million, aided by a $13.4 million Florida supplemental payment program accrual.

Specialty Treatment Facilities revenue fell 8.2%, tied to Pennsylvania facilities and closures, and Comprehensive Treatment Facilities slipped 2.3%. Facility closures over the trailing twelve months also reduced overall revenue growth by 1.3 percentage points. Rising salaries, wages, and benefits, up 6.1%, reflect both new facility openings and annual wage increases, and the company carried net leverage of 3.9 times adjusted EBITDA.

Sponsored

Management raised full-year 2026 adjusted EPS guidance to $1.70 to $1.80 from a prior range of $1.45 to $1.60, a meaningful step up against a roughly $3 billion market cap. Full-year revenue guidance moved to $3.44 to $3.46 billion, adjusted EBITDA guidance to $615 to $625 million, and operating cash flow guidance to $375 to $400 million. Capital expenditure guidance was trimmed to $210 to $230 million from $235 to $255 million.

Looking further out, CEO Debbie Osteen pointed to the 16 acute facilities opened over the past four years as a source of durable earnings growth, stating the company expects approximately $60 million of incremental EBITDA from those facilities in 2027 relative to 2026. The key risks investors will want to monitor include Medicaid financing changes under the One Big Beautiful Bill Act, reduced admissions from Medicaid work and community engagement requirements, and ongoing government investigation costs, which totaled $18.3 million in the quarter alone.

Mentioned: ACHC